NCT03188991 - Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

June 29, 2020

Study Completion Date

June 29, 2020

Conditions

Pancreatic Mucinous-Cystic Neoplasm

Interventions

DRUG

NanoPac®

NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)

Trial Locations (4)

The Ohio State University, Wexner Medical Center, Columbus

Parkview Cancer Institute, Fort Wayne

Baylor College of Medicine, Houston

Texas Tech University Health Sciences Center, El Paso